Ted W. Love, MD is currently chair of the Board of Directors of the Biotechnology Innovation Organization. From 2014 to 2022, Dr. Love was the President and Chief Executive Officer of Global Blood Therapeutics, Inc., where he led the company from a pre-clinical startup through its growth to a global commercial company with a pipeline of innovative therapies focused on sickle cell disease. Previously, he was Executive Vice President, Research and Development and Technical Operations at Onyx Pharmaceuticals, Inc. He also served as President, Chief Executive Officer and Chairman of Nuvelo, Inc., and Senior Vice President, Development at Theravance Biopharma, Inc. He began his biotech career at Genentech, Inc., where he held several senior management positions in clinical science and product development, and ultimately as chair of Genentech’s Product Development Committee. Prior to Genentech, Dr. Love was a member of the Department of Cardiology at the Massachusetts General Hospital. Known for championing access to care, Dr. Love received the William E. Proudford Sickle Cell Fund 2023 Distinguished Service Award. He also earned the Spirit of the Heart Health Equity Champion Award from the Association of Black Cardiologists in 2023. Dr. Love currently serves on the board of directors of Royalty Pharma plc, Structure Therapeutics Inc., and Gilead. He previously served on the board of directors of Seagen Inc., from 2020 to 2023; Global Blood Therapeutics from 2013 to 2022; Portola Pharmaceuticals, Inc., from 2019 to 2020; and Amicus Therapeutics, Inc., from 2012 to 2020.Dr. Love has a long and distinguished career in the biopharmaceutical industry. He most recently served as president and CEO of Global Blood Therapeutics (GBT), a biotech company founded in 2011 to address sickle cell disease. Dr. Love led GBT’s growth from a pre-clinical start-up into a multi-national commercial business and introduced the first innovative rationally designed, disease-modifying treatment for sickle cell disease. GBT was acquired by Pfizer for $5.8 billion in October 2022. In addition to his ongoing commitment to the sickle cell disease community, Dr. Love serves on the boards of directors of Gilead Sciences, Structure Therapeutics, Royalty Pharma plc. and several early-stage biotechs. He is also chair of the board of the Biotechnology Innovation Organization (BIO) and a founding board member of Life Science Cares Bay Area. Before GBT, he served as executive vice president, of research and development and technical operations, at Onyx Pharmaceuticals, Inc., where he played an instrumental role in initiating and completing Onyx’s first Phase 3 clinical trials, and the approval of Kyprolis. Onyx was purchased by Amgen for $10.4 billion. Prior to Onyx, he served as president, chief executive officer and chairman of Nuvelo, Inc., and before that as senior vice president, development, at Theravance, Inc. Dr. Love began his biotech career at Genentech where he held senior management positions in medical affairs and product development, and he served as chairman of Genentech’s Product Development Committee. As vice president of product development, Dr. Love oversaw the development and approval of multiple innovative therapies including Rituxan, Herceptin, Avastin, Xolair, and Tenecteplase. Dr. Love holds a B.A. in molecular biology from Haverford College and an M.D. from Yale Medical School. He completed a residency in internal medicine and a fellowship in cardiology at the Massachusetts General Hospital.